selective serotonin reuptake inhibitors + serotonin and norepinephrine reuptake inhibitors

This entry refers to a combination of two classes of antidepressant medications—selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). Both are small molecule pharmaceuticals used primarily for the treatment of major depressive disorder, anxiety disorders, and related psychiatric conditions. SSRIs work by selectively inhibiting the reuptake of serotonin in the brain, thereby increasing its availability in the synaptic cleft. SNRIs inhibit the reuptake of both serotonin and norepinephrine, enhancing levels of these neurotransmitters. While both classes are effective as monotherapy, combining them is not standard practice due to increased risk for adverse effects such as serotonin syndrome—a potentially life-threatening condition caused by excessive serotonergic activity[1][5][6]. The safety and efficacy profile for this specific combination has not been formally established; combinations may be considered only under specialist supervision when other treatments have failed.

Other names

ssri + snri